Cao Y, Suresh M R
Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada, T6G 2N8.
Bioconjug Chem. 1998 Nov-Dec;9(6):635-44. doi: 10.1021/bc980044l.
Bispecific antibodies are unique macromolecular heterobifunctional cross-linkers with two different binding specificities within a single molecule. As ideal bioconjugates, they can specifically glue any two different molecules together without the need for chemical conjugation. With this unique feature, they have immense potential in biological and immunological fields. Their applications range from immunohistochemistry, immunoassays, radioimmunodiagnosis, radioimmunotherapy, and immunotherapy. Recently, a new second generation of bispecific molecules, bispecific single chain Fv and diabodies, has been produced by DNA recombinant technology. They can be considered as the ultimate magic bullets for in vivo applications. They may theoretically improve tumor or pathogen targeting and minimize side effects, eventually replacing the full-length bispecific antibodies. Emphasizing on developmental methodology and clinical applications of bispecific antibodies, this review gives a bird's-eye view of these unique bioconjugates.
双特异性抗体是独特的大分子异双功能交联剂，在单个分子内具有两种不同的结合特异性。作为理想的生物共轭物，它们可以特异性地将任何两种不同的分子粘合在一起，而无需化学共轭。凭借这一独特特性，它们在生物学和免疫学领域具有巨大潜力。其应用范围涵盖免疫组织化学、免疫测定、放射免疫诊断、放射免疫治疗和免疫治疗。最近，通过DNA重组技术产生了新一代双特异性分子，即双特异性单链Fv和双抗体。它们可被视为体内应用的终极神奇药物。从理论上讲，它们可以改善肿瘤或病原体靶向性并将副作用降至最低，最终取代全长双特异性抗体。本文着重介绍双特异性抗体的研发方法和临床应用，对这些独特的生物共轭物进行了全景式的综述。
